LT5034B - Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai - Google Patents
Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai Download PDFInfo
- Publication number
- LT5034B LT5034B LT2002031A LT2002031A LT5034B LT 5034 B LT5034 B LT 5034B LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A LT 5034 B LT5034 B LT 5034B
- Authority
- LT
- Lithuania
- Prior art keywords
- treatment
- methoxymethyl
- oxime
- mesoprogestins
- disorders
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 47
- 230000002265 prevention Effects 0.000 title claims abstract description 20
- 229940088597 hormone Drugs 0.000 title claims abstract description 7
- 239000005556 hormone Substances 0.000 title claims abstract description 7
- 230000001419 dependent effect Effects 0.000 title claims abstract description 6
- 239000002379 progesterone receptor modulator Substances 0.000 title abstract description 5
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 title abstract description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 claims abstract description 42
- 201000009273 Endometriosis Diseases 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 208000005171 Dysmenorrhea Diseases 0.000 claims abstract description 24
- 208000035475 disorder Diseases 0.000 claims abstract description 21
- 208000007106 menorrhagia Diseases 0.000 claims abstract description 15
- 206010027514 Metrorrhagia Diseases 0.000 claims abstract description 11
- 206010046798 Uterine leiomyoma Diseases 0.000 claims abstract description 10
- 201000010260 leiomyoma Diseases 0.000 claims abstract description 10
- 230000002980 postoperative effect Effects 0.000 claims abstract description 7
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 30
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 13
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 13
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 10
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 9
- 150000002923 oximes Chemical class 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- -1 4-acetylaminophenyl Chemical group 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 3
- WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 claims description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims description 2
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 2
- 108010037003 Buserelin Proteins 0.000 claims description 2
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 2
- 229960002719 buserelin Drugs 0.000 claims description 2
- 108700008462 cetrorelix Proteins 0.000 claims description 2
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 2
- 229960003230 cetrorelix Drugs 0.000 claims description 2
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 2
- 108010083551 iturelix Proteins 0.000 claims description 2
- 229960004338 leuprorelin Drugs 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 108010092834 ramorelix Proteins 0.000 claims description 2
- 229950000277 ramorelix Drugs 0.000 claims description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical group CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229940033942 zoladex Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 102000003998 progesterone receptors Human genes 0.000 abstract description 11
- 108090000468 progesterone receptors Proteins 0.000 abstract description 11
- 208000032843 Hemorrhage Diseases 0.000 abstract description 9
- 230000000740 bleeding effect Effects 0.000 abstract description 8
- 230000001270 agonistic effect Effects 0.000 abstract description 5
- 230000003042 antagnostic effect Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 150000003146 progesterones Chemical class 0.000 abstract description 2
- 206010034650 Peritoneal adhesions Diseases 0.000 abstract 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 27
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 239000000186 progesterone Substances 0.000 description 13
- 229960003387 progesterone Drugs 0.000 description 13
- 239000000556 agonist Substances 0.000 description 12
- 239000003418 antiprogestin Substances 0.000 description 12
- 206010000210 abortion Diseases 0.000 description 10
- 231100000176 abortion Toxicity 0.000 description 10
- 230000000708 anti-progestin effect Effects 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000002357 endometrial effect Effects 0.000 description 9
- 241000700198 Cavia Species 0.000 description 8
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 8
- 239000000583 progesterone congener Substances 0.000 description 8
- 208000034158 bleeding Diseases 0.000 description 7
- 229960000766 danazol Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 5
- 208000000450 Pelvic Pain Diseases 0.000 description 5
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 5
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 5
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 5
- 230000001838 anti-progestagenic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 230000000757 progestagenic effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960003464 mefenamic acid Drugs 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 229960003248 mifepristone Drugs 0.000 description 3
- 229940110234 mirena Drugs 0.000 description 3
- 229940053934 norethindrone Drugs 0.000 description 3
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 3
- 229950011093 onapristone Drugs 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000000044 progesterone antagonist Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- BJJXHLWLUDYTGC-ANULTFPQSA-N Gestrinone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](CC)([C@](CC3)(O)C#C)C=C3)C3=C21 BJJXHLWLUDYTGC-ANULTFPQSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 229960004761 gestrinone Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000401 tranexamic acid Drugs 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000034424 Painful defaecation Diseases 0.000 description 1
- 229940121912 Progesterone receptor agonist Drugs 0.000 description 1
- 229940123788 Progesterone receptor antagonist Drugs 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010062662 Uterine mass Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000001911 anti-progestational effect Effects 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003454 betamimetic effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960000445 ethisterone Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003152 gestagenic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000003195 tocolytic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614199A | 1999-08-31 | 1999-08-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2002031A LT2002031A (en) | 2003-02-25 |
| LT5034B true LT5034B (lt) | 2003-07-25 |
Family
ID=23524338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2002031A LT5034B (lt) | 1999-08-31 | 2002-03-21 | Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1229906B1 (pl) |
| JP (1) | JP2003535029A (pl) |
| KR (3) | KR20080066095A (pl) |
| AR (1) | AR025457A1 (pl) |
| AT (1) | ATE375160T1 (pl) |
| AU (1) | AU781840B2 (pl) |
| BG (1) | BG65817B1 (pl) |
| BR (1) | BR0014161A (pl) |
| CA (1) | CA2382580C (pl) |
| CO (1) | CO5200772A1 (pl) |
| CZ (1) | CZ2002704A3 (pl) |
| DE (1) | DE60036723T2 (pl) |
| DK (1) | DK1229906T3 (pl) |
| EA (1) | EA007854B1 (pl) |
| EE (1) | EE05172B1 (pl) |
| ES (1) | ES2295050T3 (pl) |
| HR (1) | HRP20020267A2 (pl) |
| HU (1) | HUP0202429A3 (pl) |
| IL (1) | IL148416A0 (pl) |
| LT (1) | LT5034B (pl) |
| LV (1) | LV12941B (pl) |
| ME (1) | MEP13808A (pl) |
| MX (1) | MXPA02002191A (pl) |
| NO (1) | NO20020999L (pl) |
| NZ (1) | NZ517471A (pl) |
| PE (1) | PE20010578A1 (pl) |
| PL (1) | PL198790B1 (pl) |
| PT (1) | PT1229906E (pl) |
| RO (1) | RO122179B1 (pl) |
| RS (1) | RS50283B (pl) |
| SI (1) | SI20852B (pl) |
| SK (1) | SK287192B6 (pl) |
| UA (1) | UA78184C2 (pl) |
| WO (1) | WO2001015679A2 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014935A1 (de) * | 2002-08-02 | 2004-02-19 | Schering Aktiengesellschaft | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| RU2301691C1 (ru) * | 2005-12-20 | 2007-06-27 | Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук | Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| RU2339392C1 (ru) * | 2007-05-21 | 2008-11-27 | Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий | Способ остановки маточных кровотечений в пубертатном периоде |
| AU2010260885B2 (en) * | 2009-06-17 | 2015-03-12 | Keio University | Prophylactic and/or therapeutic agent for dysmenorrhea |
| US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| US20220339176A1 (en) * | 2019-09-23 | 2022-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation |
| US12426782B2 (en) | 2020-11-06 | 2025-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and temporal alignment methods for evaluation of gestational age and time to delivery |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0266303A2 (de) | 1986-09-26 | 1988-05-04 | Schering Aktiengesellschaft | Antigestagene zur Hemmung der uterinen Prostaglandinsynthese |
| DE4332284A1 (de) | 1993-09-20 | 1995-03-23 | Jenapharm Gmbh | Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332283A1 (de) | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO1996023503A1 (de) | 1995-02-02 | 1996-08-08 | Schering Aktiengesellschaft | Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5576310A (en) * | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| WO1996019458A2 (en) * | 1994-12-22 | 1996-06-27 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US5696130A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| DE69702450T2 (de) * | 1996-05-01 | 2001-03-08 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | 21-substituierte progesteron derivate als antigestagene |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| BR9916999A (pt) * | 1999-01-14 | 2001-10-30 | Bayer Ag | Heterociclos de 2-arilimino substituìdos ecomposições contendo-os, para uso como agentesde ligação do receptor de progesterona |
| WO2000066590A2 (en) * | 1999-05-04 | 2000-11-09 | Ligand Pharmaceuticals, Inc. | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 AR ARP000104538A patent/AR025457A1/es unknown
- 2000-08-31 NZ NZ517471A patent/NZ517471A/en unknown
- 2000-08-31 AU AU69466/00A patent/AU781840B2/en not_active Ceased
- 2000-08-31 DK DK00957914T patent/DK1229906T3/da active
- 2000-08-31 PL PL353930A patent/PL198790B1/pl not_active IP Right Cessation
- 2000-08-31 KR KR1020087016247A patent/KR20080066095A/ko not_active Withdrawn
- 2000-08-31 IL IL14841600A patent/IL148416A0/xx unknown
- 2000-08-31 EE EEP200200104A patent/EE05172B1/xx not_active IP Right Cessation
- 2000-08-31 HR HR20020267A patent/HRP20020267A2/xx not_active Application Discontinuation
- 2000-08-31 SK SK299-2002A patent/SK287192B6/sk unknown
- 2000-08-31 ME MEP-138/08A patent/MEP13808A/xx unknown
- 2000-08-31 AT AT00957914T patent/ATE375160T1/de not_active IP Right Cessation
- 2000-08-31 RO ROA200200229A patent/RO122179B1/ro unknown
- 2000-08-31 WO PCT/US2000/023770 patent/WO2001015679A2/en not_active Ceased
- 2000-08-31 EA EA200200282A patent/EA007854B1/ru not_active IP Right Cessation
- 2000-08-31 RS YUP-140/02A patent/RS50283B/sr unknown
- 2000-08-31 KR KR1020027002790A patent/KR100755109B1/ko not_active Expired - Fee Related
- 2000-08-31 UA UA2002032430A patent/UA78184C2/uk unknown
- 2000-08-31 BR BR0014161-5A patent/BR0014161A/pt not_active Application Discontinuation
- 2000-08-31 PE PE2000000893A patent/PE20010578A1/es not_active Application Discontinuation
- 2000-08-31 DE DE60036723T patent/DE60036723T2/de not_active Expired - Lifetime
- 2000-08-31 PT PT00957914T patent/PT1229906E/pt unknown
- 2000-08-31 ES ES00957914T patent/ES2295050T3/es not_active Expired - Lifetime
- 2000-08-31 HU HU0202429A patent/HUP0202429A3/hu unknown
- 2000-08-31 CA CA002382580A patent/CA2382580C/en not_active Expired - Lifetime
- 2000-08-31 SI SI200020042A patent/SI20852B/sl not_active IP Right Cessation
- 2000-08-31 EP EP00957914A patent/EP1229906B1/en not_active Expired - Lifetime
- 2000-08-31 JP JP2001519893A patent/JP2003535029A/ja active Pending
- 2000-08-31 CZ CZ2002704A patent/CZ2002704A3/cs unknown
- 2000-08-31 KR KR1020077011455A patent/KR100864547B1/ko not_active Expired - Fee Related
- 2000-08-31 CO CO00065515A patent/CO5200772A1/es not_active Application Discontinuation
-
2002
- 2002-02-26 BG BG106442A patent/BG65817B1/bg unknown
- 2002-02-28 MX MXPA02002191A patent/MXPA02002191A/es active IP Right Grant
- 2002-02-28 NO NO20020999A patent/NO20020999L/no not_active Application Discontinuation
- 2002-03-21 LT LT2002031A patent/LT5034B/lt not_active IP Right Cessation
- 2002-03-28 LV LVP-02-53A patent/LV12941B/lv unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0266303A2 (de) | 1986-09-26 | 1988-05-04 | Schering Aktiengesellschaft | Antigestagene zur Hemmung der uterinen Prostaglandinsynthese |
| DE4332284A1 (de) | 1993-09-20 | 1995-03-23 | Jenapharm Gmbh | Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332283A1 (de) | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO1996023503A1 (de) | 1995-02-02 | 1996-08-08 | Schering Aktiengesellschaft | Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
Non-Patent Citations (2)
| Title |
|---|
| ELGER W. ET AL.: "Endometrial and myometrial effects of progesterone antagonists in pregnant quinea pigs", AM. J. OBSTET. GYNECOL, 1987, pages 1065 - 1074 |
| ELGER W. ET AL.: "Mechanism of action of progesterone antagonists in pregnant quinea pigs", CONTRACEPTION, 1986, pages 47 - 62 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK78997A3 (en) | Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception | |
| KR100864547B1 (ko) | 양성 호르몬 의존성 부인과 질병의 치료 및 예방을 위한메조프로게스틴 (프로게스테론 수용체 조절물질) | |
| AU781835B2 (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives | |
| US8193252B1 (en) | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders | |
| Ashok et al. | The antiprogestogen mifepristone: a review | |
| LT5011B (lt) | Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip hormonų pakeitimo terapijos (hpt) kompozicijų komponentai | |
| HK1062391A (en) | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders | |
| CN1450892A (zh) | 中孕酮(孕酮受体调节剂)用于治疗和预防激素依赖性良性妇科疾病 | |
| ZA200201614B (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC9A | Transfer of patents |
Owner name: SCHERING AKTIENGESELLSCHAFT, DE Effective date: 20050104 |
|
| MM9A | Lapsed patents |
Effective date: 20100831 |